Anti-CD44 monoclonal antibody A3D8

Drug Profile

Anti-CD44 monoclonal antibody A3D8

Alternative Names: A3D8

Latest Information Update: 26 Apr 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Duke University Medical Center
  • Developer NEXTherapeutics
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action CD44 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; HIV-1 infections; Myeloid leukaemia

Most Recent Events

  • 26 Apr 2007 Discontinued - Preclinical for Acute myeloid leukaemia in USA (unspecified route)
  • 26 Apr 2007 Discontinued - Preclinical for Myeloid leukaemia in France (unspecified route)
  • 26 Apr 2007 Discontinued for HIV-1 infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top